抗PD-1/PD-L1单抗治疗进展期非小细胞肺癌的效果  

Effect of Anti-PD-1/PD-L1 mAb in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：李林[1] LI Lin(Jiangxi Cancer Hospital,Nanchang 330029,China)

机构地区：[1]江西省肿瘤医院,江西南昌330029

出　　处：《中国医学创新》2022年第16期1-5,共5页Medical Innovation of China

基　　金：江西省卫健委科技计划项目(SKJP220202972)。

摘　　要：目的:探讨抗程序性死亡因子(PD-1)/程序性死亡配体1(PD-L1)单抗治疗进展期非小细胞肺癌(NSCLC)患者的效果。方法:选取2020年6月-2021年6月于江西省肿瘤医院就诊的进展期NSCLC患者60例,按随机数字表法将其分为对照组(n=30)和观察组(n=30)。对照组给予多西他赛(DOC)治疗,观察组给予卡瑞利珠单抗治疗,比较两组近期疗效、肿瘤浸润T细胞(TITL)密度及分布情况、血清相关指标及不良反应发生情况。结果:治疗9周后,观察组疾病控制率(73.33%)较对照组(46.67%)高(P<0.05);观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均较对照组高,CD8^(+)水平较对照组低(P<0.05);观察组基质金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)、角蛋白19片段抗原21-1(CYFRA21-1)水平均较对照组低(P<0.05);观察组不良反应发生率(13.33%)较对照组(36.67%)低(P<0.05)。结论:进展期NSCLC患者应用抗PD-1/PD-L1单抗治疗可改善肿瘤浸润T细胞密度及分布情况,抑制肿瘤生长转移及新生血管生成,提高临床疗效。Objective:To explore the effect of anti-programmed death factor(PD-1)/programmed death ligand 1(PD-L1) monoclonal antibody in the treatment of patients with advanced non-small cell lung cancer(NSCLC).Method:A total of 60 patients with advanced NSCLC who were treated in Jiangxi Cancer Hospital from June 2020to June 2021 were selected.They were divided into control group(n=30) and observation group(n=30) according to the random number table method.The control group was treated with Docetaxel(DOC),and the observation group was treated with Camrelizumab.The short-term efficacy,density and distribution of tumor infiltrating T lymphocyte(TITL),serum-related indicators and adverse reactions were compared between the two groups.Result:After 9 weeks of treatment,the disease control rate(73.33%) of the observation group was higher than 46.67% of the control group(P<0.05);CD3^(+),CD4^(+),CD4^(+)/CD8^(+) in the observation group were higher than those in the control group,and CD8^(+)levels was lower than that in the control group(P<0.05);the levels of matrix metalloproteinase-9(MMP-9),vascular endothelial growth factor(VEGF) and cytokeratin 19 fragment antigen 21-1(CYFRA21-1) in the observation group were lower than those in the control group(P<0.05);the incidence of adverse reactions in the observation group(13.33%) was lower than 36.67% in the control group(P<0.05).Conclusion:The application of anti-PD-1/PD-L1monoclonal antibody in patients with advanced NSCLC can improve the density and distribution of tumor infiltrating T cells,inhibit tumor growth,metastasis and angiogenesis,and improve the clinical efficacy.

关 键 词：多西他赛 非小细胞肺癌 卡瑞利珠单抗 程序性死亡配体1 

分 类 号：R734.2[医药卫生—肿瘤]